Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lundbeck Snaps Up Parkinson's Developer Prexton In Deal Worth €905m

Executive Summary

Lundbeck has swooped in to buy Merck KGaA spinout Prexton Therapeutics for €100m upfront, prior to Phase II data readouts for its potential first-in-class Parkinson's drug, foliglurax.

You may also be interested in...



Deal Watch: Opportunity Knocks For Partnerships In Asia

ApolloBio signs on to take Inovio's HPV immunotherapy into China and Senju and Fosun sign China partnerships – all part of a wave of Chinese companies looking to bring innovative new medicines to the Greater China markets. Meanwhile, GSK signs on with Indian CRO Syngene.

Merck Spin-Off Prexton Turns mGluR4 Fortunes Around In Parkinson's Disease

Prexton Therapeutics has the only mGluR4-targeting drug candidate in clinical testing, after a number of big pharma dropped preclinical programs. The company has just secured €29m to fund two Phase II trials.

Femtech Presents Enticing Market Opportunity

A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.

Topics

Related Companies

UsernamePublicRestriction

Register

GB150348

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel